Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone
|
|
- Arlene Dorsey
- 5 years ago
- Views:
Transcription
1 Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) April 26 th 2018 Raxone tablets are available in the UK through the Early Access to Medicines Scheme (EAMS). The UK Commission on Human Medicines (CHM) undertook a review of the EAMS scientific opinion for Raxone, which is manufactured by Santhera Pharmaceuticals and is also known as idebenone. On 19 th April 2018 the CHM advised the Medicines and Healthcare Products Regulatory Agency (MHRA) that the positive scientific opinion given to Raxone in June 2017 for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids (also known as steroids ) could be maintained. The MHRA has decided to maintain the positive EAMS scientific opinion as the assessment of risk/benefit on which it made its initial decision remains unchanged. The MHRA has reviewed the latest information supplied by the manufacturer and considers that Raxone has an acceptable safety profile overall; it is also satisfied that the company is able to continue to supply the medicine according to a consistent quality standard. In conclusion, considering the very high level of unmet need in this patient population, and that the benefits outweigh the risks, continued early access to Raxone for DMD patients as defined in the scope of the EAMS indication is considered to be justified. Therefore Santhera will continue to make Raxone available through the UK EAMS scheme. A formal renewal of the EAMS scientific opinion is due to be concluded by end June 2018 enabling the EAMS to be renewed for a further year until June This medicine may not be suitable for everybody and people with DMD need to discuss their own condition with a specialist doctor who knows them to assess if this treatment is appropriate.
2 Frequently Asked Questions (FAQs) 1. What is the Early Access to Medicines Scheme? The aim of the Early Access to Medicines Scheme (EAMS) is to provide earlier availability of promising medicines to patients in the UK where there is high unmet clinical need, before the normal European product licensing process is completed. The medicinal products included in the scheme are those that are intended to treat, diagnose or prevent seriously debilitating or life threatening conditions where there are no adequate treatment options. The scheme is regulated by the Medicines and Healthcare Regulatory Agency (MHRA) in the UK. More information about the scheme can be found on its website here: EAMS/index.htm An EAMS programme is only open to include new people until a product gets a European product licence, then no new people can be added to the scheme. 2. Why did the MHRA undertake a review of the EAMS scientific opinion for Raxone? Raxone is licensed for a rare condition (Leber s Hereditary Optic Neuropathy) but is not licensed for use in Duchenne Muscular Dystrophy (DMD). Santhera had separately applied to the European Medicines Agency (EMA) for a variation to the marketing authorisation to add the DMD indication to the existing Raxone product licence for Leber s Hereditary Optic Neuropathy. This was refused in January 2018 after an EMA committee concluded that the data of the Phase III DELOS trial alone would not support a registration at this time and further definitive data were needed. The review of EAMS by the MHRA followed this decision and consultation with clinical experts on the UK Commission on Human Medicines, with input from UK patient organisations. 3. Is the EAMS positive scientific opinion for Raxone (idebenone) in DMD maintained? Yes, as recommended by the UK Commission on Human Medicines (CHM) on 19th April 2018.
3 4. Will the EAMS positive scientific opinion be renewed until what date? The EAMS is to be formally renewed in June 2018 for a further year until June This regulatory procedure is currently ongoing. 5. Is the EAMS indication unchanged? Yes, the EAMS indication in DMD is unchanged. Raxone is indicated under EAMS for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids 6. EAMS has a Risk Management Plan that helps to ensure that Raxone is used safely within EAMS has that changed? No, the Risk Management Plan for EAMS has not changed directly as a result of this review, but it may need realignment following a recent change to one section of the product licence for another use of Raxone. Santhera will work with the MHRA to make any necessary amendments. 7. Has the consent of patients been amended and do any patients need to be re-consented? No, the patient consent for this EAMS has not been amended and existing patients in the EAMS do not need to be asked to re-consent. 8. How long will the EAMS be open? An EAMS is reviewed and considered for renewal each year by the MHRA, and has to close to new patients once a product licence is granted. Santhera is preparing to make a new application for a product licence, a process which is expected to take around 2 years to complete, and expects to apply for annual renewals of EAMS until then. Santhera will provide Raxone free of charge to the NHS during the EAMS period, which is defined as after the award of an EAMS positive scientific opinion and up to the granting of the product licence. Once the scheme closes, Santhera will continue to supply the medicine for people who are already enrolled in the EAMS for as long as their doctor considers it to be beneficial, up to the point of a positive NHS funding policy (e.g. Health Technology Assessment (HTA) guidance, national funding policy, local funding arrangements etc.).
4 9. How does the EAMS work? The EAMS allows medicines to be prescribed by UK specialist doctors to treat people before it has a product licence. This is not a clinical trial; it is more like how the medicine will be used in real life once it has a licence. However, extra care will be taken as this is an unlicensed medicine in DMD. Treatment will only be provided in specialist centres that are experienced in managing DMD and there is the requirement for careful monitoring to ensure the safety of patients during the EAMS. People with DMD may discuss together with their doctor whether they are suitable for this treatment and a joint decision would be made whether they want to go ahead. They would be asked to sign a consent form once they have considered all the information. 10. Where is the EAMS available? This EAMS is available in the UK National Health Service in England, Scotland, Northern Ireland and Wales. 11. What is Raxone? Raxone is a medicine that contains a substance called idebenone in tablet form. Idebenone is a potent anti-oxidant and is believed to improve the functioning of mitochondria that are important for the generation of energy and control of metabolic processes inside cells. Raxone comes as tablets which need to be taken three times a day with food. If someone has difficulty in swallowing, tablets can if necessary be crushed into semisolid or liquid feed for administration through a tube into the stomach. Raxone is already licensed for use in a rare, genetic eye condition called LHON (Leber s Hereditary Optic Neuropathy). 12. Who can have this treatment in the Scheme? Raxone is only available with a prescription from a specialist doctor with experience in managing people with DMD. A specialist doctor can advise on whether the scheme might be suitable for an individual person. Raxone has been approved for use within the EAMS programme to slow the rate of decline of breathing ability in patients with DMD from the age of 10 years who are not taking glucocorticoids (also known as steroids ). This is because clinical trials
5 have only been completed with this medicine in patients of this age with DMD who were not taking steroids. Breathing ability is usually measured by lung function tests, and typically these show that function begins to decline below the lower limit of normal in people with DMD around the time they lose ambulation and require a wheelchair most of the time. Lung function decline must be confirmed by spirometry (a test done in hospital, which measures the maximum flow and volume of air that can be exhaled in one breath) before Raxone is given. Raxone can only be given to patients not taking glucocorticoids or those previously treated with glucocorticoids, such as prednisolone or deflazacort, or in patients who are not suitable for continuation or commencement of glucocorticoid treatment. Importantly, Raxone is not a replacement for steroids and people with DMD should not decide to stop steroids solely so that they can start Raxone. A specialist doctor with experience of managing people with DMD can advise on the benefits of continuing steroid therapy for an individual person. 13. Is Raxone available for patients who are taking steroids? People with DMD who are taking steroids are not eligible for this EAMS. SIDEROS is a clinical trial designed to study whether Raxone is safe and effective at delaying the loss of respiratory function in boys and men with DMD who are currently taking steroids. Some specialist centres in the UK are able to enter people into this study. Further information can be found at What are the possible side effects? Like all medicines, Raxone can cause side effects, although not everyone gets them. The MHRA and the Company have made available a leaflet written for people with DMD that explains more about Raxone and its effects. Specialist doctors will also be able to explain this further. A risk management plan has been developed to ensure that Raxone is used as safely as possible within EAMS. 15. Are there extra tests and hospital visits required? In most circumstances no extra tests are required for participants in EAMS beyond what is routine practice. Doctors will want to keep in touch regularly with their patients to know how they are finding the new treatment. In particular they will want to know about any side effects they experience.
6 16. How is the introduction of a new medicine regulated in the UK? A medicine that is proposed to be marketed in the medical condition Duchenne muscular dystrophy (DMD) must be licensed for that use in the countries of the European Union by the European Medicines Agency. The Committee on Human Medicinal Products (CHMP), of which the MHRA is a member, makes a thorough review of detailed information provided by the manufacturer of the medicine and will recommend if a product should receive an authorisation in the European Union. The information submitted includes the results of clinical trials that have been completed using the medicine in people with the condition that is being studied. 17. Why did the EMA reject the marketing authorisation application for Raxone in January 2018? Raxone already has a Marketing Authorisation (also known as a product licence ) for a rare genetic eye condition called LHON (Leber s Hereditary Optic Neuropathy) which was granted in September Santhera submitted a variation application to the EMA in May 2016 to extend the use of the product for a new indication in DMD; a variation to an existing marketing authorisation requires definitive data to be in place at the time. The EMA made its decision based on the evidence provided by the manufacturer, concluding that the data of the Phase III DELOS trial alone would not support a registration at the current time. Further data are required to support the results of the DELOS trial, particularly to support the link between the observed treatment effect on respiratory function outcomes and patient benefit. Not unusually, when investigating new medicines in rare diseases, the number of patients in the DELOS clinical trial was small and, although the study outcome was positive, the EMA has some uncertainty about the effect of treatment based on such small numbers. The evidence shows, however, that Raxone is generally welltolerated in patients with DMD. 18. Why did the MHRA renew the EAMS positive opinion for Raxone if the EMA had rejected the marketing authorisation? The EMA decision was made in the context of a variation to an existing marketing authorisation which required definitive data to be in place at the time. The aim of the Early Access to Medicines Scheme (EAMS) is to provide earlier availability of promising medicines to patients in the UK where there is high unmet clinical need, before the normal European product licensing process is completed. The MHRA had already reviewed the safety and efficacy data for Raxone in DMD and given a
7 positive opinion in June 2017 for supply under EAMS. The MHRA, on the recommendation of the UK Commission on Human Medicines (CHM) has decided to maintain the EAMS scientific opinion which will enable the supply of Raxone under EAMS to be continued, as the risk/benefit profile on which CHM made its initial decision remains unchanged, and there is a clear high unmet medical need for patients with DMD. CHM also acknowledged the prospect of more data from the ongoing clinical study (SIDEROS) and the opportunities for ongoing patient monitoring in the real world environment. Patients receiving Raxone through EAMS are required to be under specialist clinical supervision in order to receive treatment and they will be carefully monitored by their doctors. NP-UK-DMD-RAX-0001 Date of preparation: April 2018
How is the introduction of a new medicine regulated in the UK?
Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) A medicine called Raxone, which
More informationAdvancing Mitochondrial Medicine. Thomas Meier, PhD CEO
Advancing Mitochondrial Medicine Thomas Meier, PhD CEO Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationSanthera Pharmaceuticals Company Presentation. September 2018
Santhera Pharmaceuticals Company Presentation September 2018 Disclaimer This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationUSE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE
NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus
More informationSWISS BIOTECH DAY 2018
SWISS BIOTECH DAY 2018 Basel, 3 May 2018 Thomas Meier, CEO Disclaimer This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationIdebenone (Raxone ) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Kristina Nygren, MD CMO, Head of Development Santhera Pharmaceuticals,
Idebenone (Raxone ) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Kristina Nygren, MD CMO, Head of Development Santhera Pharmaceuticals, Inc Disclaimer This presentation is not and under no circumstances
More informationConsent to research. A draft for consultation
Consent to research A draft for consultation 1 Consent to research About the guidance Our guidance Consent: patients and doctors making decisions together (2008) 1 sets out the principles of good practice
More informationWyss Zürich Regulatory Affairs Seminar
Wyss Zürich Regulatory Affairs Seminar Hospital Exemption & Compassionate Use EU Framework Catherine Longeval Koen T Syen Zürich, 5 July 2017 1 Table of contents Introduction Hospital Exemption Implementation
More informationUse of unlicensed medicines and off-label uses
Use of unlicensed medicines and off-label uses 25 Promoting hope and wellbeing together What is this leaflet about? Your doctor or pharmacist has given you this leaflet because a medicine that you have
More informationRaxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD)
Raxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Thomas Meier, PhD February 2018 Agenda Medical need for effective treatment of respiratory illness in DMD Understanding respiratory
More informationReview of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy
Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Introduction 1. The consolidation and review of the UK medicines legislation (including the Medicines
More informationE096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability
E096 Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability Please complete the following details: Patient s name, address, date of birth,
More informationSummary of the risk management plan (RMP) for Raxone (idebenone)
EMA/467186/2015 Summary of the risk management plan (RMP) for Raxone (idebenone) This is a summary of the risk management plan (RMP) for Raxone, which details the measures to be taken in order to ensure
More informationPackage leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone
Package leaflet: Information for the user Raxone 150 mg film-coated tablets idebenone This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationFrequently asked questions
13 February 2017 EMA/527628/2011 Rev. 1 Directorate This document provides answers to the most frequently asked questions received by the European Medicines Agency (EMA).If the answer to your question
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationSpecialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT
Specialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT This note covers all research undertaken at the University that involves the recruitment
More informationDIRECT ACCESS - Guidance to BSDHT Members
DIRECT CCESS - Guidance to BSDHT Members Direct ccess came into effect from 1 May 2013. But what does it mean for dental hygienists and dental therapists? The GDC have published guidance notes on the subject
More informationResponse to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014
Responseto ScottishGovernment AConsultationonElectronicCigarettesand StrengtheningTobaccoControlinScotland December2014 Contact Janice Oman Scotland Representation Manager National Pharmacy Association
More informationOnline Form. Welcome to the Integrated Research Application System. IRAS Project Filter
Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationSanthera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone
Santhera will hold a webcast tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST. Details at the end of statement. Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive
More informationHow Clinical Trials Work
A Guide to: How Clinical Trials Work Clinical trials are rigorously controlled tests designed to examine the safety and / or effectiveness of medicines, devices, treatments, or preventive measures in humans.
More informationGood Practice Guidance on Covert Administration of Medication
Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their
More informationA Guide to the Scottish Medicines Consortium
A Guide to the Scottish Medicines Consortium Providing advice about newly licensed medicines www.scottishmedicines.org About the Scottish Medicines Consortium The Scottish Medicines Consortium (SMC) provides
More informationSanthera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone. Webcast, 21 November 2018
Santhera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone Webcast, 21 November 2018 Disclaimer This presentation is not and under no circumstances
More informationNEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting
The Pharmacovigilance Risk Assessment Committee (PRAC) Meeting 7-10 July 2014 Finalised safety procedure for methadone products containing povidone Only high molecular weight povidone was associated with
More informationQuality, Safety and Sourcing in Unlicensed Medicines
Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?
More informationMEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH
11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims
More informationEssential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)
Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant
More informationTranslating Science. Transforming Lives. ACT DMD Clinical Trial Results
Translating Science. Transforming Lives ACT DMD Clinical Trial Results FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationDIRECT ACCESS Guidance to BSDHT Members
DIRECT CCESS Guidance to BSDHT Members Direct ccess comes into effect from 1 May 2013. But what does it mean for dental hygienists and dental therapists? The GDC have published guidance notes on the subject
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationGuideline scope Smoking cessation interventions and services
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Topic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Smoking cessation interventions and services This guideline
More informationChanging practice to support service delivery
Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
The European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 December 2005 EMEA/357981/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON PROCEDURES
More informationDraft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1
1. Introduction Draft Guidance for Pharmacists on Extemporaneous Dispensing Version 1 The purpose of this guidance is to assist pharmacists in discharging their legal and professional obligations to patients
More informationDEFLAZACORT Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668
Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of Duchenne muscular dystrophy
More informationon the Respiratory Health of Boys and Men With Duchenne Muscular Dystrophy (DMD)
on the Respiratory Health of Boys and Men With Duchenne Muscular Dystrophy (DMD) At Santhera, we re studying a potential new treatment option to slow the progression of respiratory function decline in
More informationPutting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)
Putting NICE guidance into practice Resource impact report: Hearing loss in adults: assessment and management (NG98) Published: June 2018 Summary This report focuses on the recommendation from NICE s guideline
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?...................3 About the swine flu vaccine...........4 What else do I need to know?.........8
More informationStaying steady. Health & wellbeing. Improving your strength and balance. AgeUKIG14
Staying steady Improving your strength and balance Health & wellbeing AgeUKIG14 Age UK is the new force combining Age Concern and Help the Aged. With almost 120 years of combined history to draw on, we
More informationwhat you need flu. Protect yourself and others.
swine flu vaccination: what you need to know flu. Protect yourself and others. contents What is swine flu?................ 3 About the swine flu vaccine........ 4 What else do I need to know?....... 8
More informationThis information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.
Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should
More informationChronic conditions explained
Chronic conditions explained The limits of your cover for treatment of chronic medical conditions April 2015 Contents Undertanding chronic conditions Why it s important for you to understand 3 about chronic
More informationUK SMART Recovery Partnership Scheme
UK SMART Recovery Partnership Scheme Contents What is SMART Recovery?... 3 Why Partner with UK SMART Recovery?... 3 What are the Intended Outcomes?... 3 Key Points... 4 Partnership Conditions... 4 Registration
More informationTreating Barrett s oesophagus with photodynamic therapy
Understanding NICE guidance Information for people who use NHS services Treating Barrett s oesophagus with photodynamic therapy NICE interventional procedures guidance advises the NHS on when and how new
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, European Medicines Agency PHARM 689 PHARMACEUTICAL COMMITTEE 21 October 2015
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationWhat are steroids and how do they work?
For over 20 years boys with Duchenne muscular dystrophy (MD) have been treated with steroids, which is currently the only medication proven to slow the progression of the condition. In Australia, more
More informationREGULATION (EC) No.141/2000
REGULATION (EC) No.141/2000 Community legislation in force Document 300R0141 Directory chapters where this document can be found: [15.30 Health promotion] Regulation (EC) No.141/2000 of the European Parliament
More informationWhat happens if I cannot make decisions about my care and treatment?
Information Line: 0800 999 2434 Website: compassionindying.org.uk What happens if I cannot make decisions about my care and treatment? This factsheet explains how decisions are made about your care or
More informationIncisionless surgery to correct protruding ears
Issue date March 2012 Understanding NICE guidance Information for people who use NHS services Incisionless surgery to correct protruding ears NICE interventional procedures guidance advises the NHS on
More informationTransplanting donated pancreatic islet cells for patients with type 1 diabetes
Understanding NICE guidance Information for people who use NHS services Transplanting donated pancreatic islet cells for patients with type 1 diabetes NICE interventional procedures guidance advises the
More information58. Translarna drug Policy for use. The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care:
58. Translarna drug Policy for use The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care: What his policy is regarding the use of the drug Translarna? The President:
More informationC 178/2 Official Journal of the European Union
C 178/2 Official Journal of the European Union 29.7.2003 Communication from the Commission on Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products (2003/C
More informationProcedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products
25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of
More informationHERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam
HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK Presented by: Mariam Aslam ESCOP European Scientific Cooperative On Phytotheapy (ESCOP) Founded in June 1989 as an umbrella
More informationBACKGROUND + GENERAL COMMENTS
Response on behalf of Sobi (Swedish Orphan Biovitrum AB) to the European Commission s Public Consultation on a Commission Notice on the Application of Articles 3, 5 and 7 of Regulation (EC) No. 141/2000
More informationGuidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business
Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business to Facilitate Compliance with Regulations 5(1)(g), 6, 8 and 11 of the Regulation of Retail Pharmacy Businesses
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationFacilitating adoption of off-patent, repurposed medicines into NHS clinical practice
Facilitating adoption of off-patent, repurposed medicines into NHS clinical practice December 2017 Contents FOREWORD... 4 1. EXECUTIVE SUMMARY... 6 2. INTRODUCTION... 9 3. BACKGROUND... 12 4. LICENSING...
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationChief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS
Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS England commissioned services. Chief Dental Officer England:
More informationTreating atrial fibrillation using heat energy delivered to the outside of the heart through a thin tube
Issue date March 2009 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
More informationOutcome Report on Pilot to involve patients in benefit/risk discussions at CHMP meetings
3 March 2017 EMA/191955/2017 Stakeholders & Communication Division Outcome Report on Pilot to involve patients in benefit/risk discussions at CHMP 1. Background/Rationale A range of mechanisms have been
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationDear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE
Directorate of Chief Medical Officer T: 0131-244 2470 E: John.Hannah@gov.scot Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE Following my letter of 31 October 2018
More informationThe European Medicines Agency (EMA)
The European Medicines Agency (EMA) Nathalie Bere and Maria Mavris Public Engagement Department EMA Training Day 21 November, 2017 An agency of the European Union What is the European Medicines Agency
More informationMedical Devices - Reporting to MHRA.. Emma Rooke, December 2015
Medical Devices - Reporting to MHRA. Emma Rooke, December 2015 Topics to be covered today: The MHRA and what we do What is a Medical Device? Adverse Incidents Reporting adverse incidents to the MHRA The
More informationTreating localised prostate cancer using freezing (cryotherapy) needles in a targeted area of the prostate
Issue date April 2012 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
More informationUpdate on Australian regulatory framework for medical devices
MTAA Update on Australian regulatory framework for medical devices Val Theisz, MSc, RAC Director Regulatory Affairs, MTAA April 2017 Who is MTAA? The Medical Technology Association of Australia (MTAA)
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationTreating severe obesity using keyhole surgery to stitch folds in the stomach to make it smaller
Issue date November 2012 Information for the public NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical practice. Treating severe obesity using
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationProcess for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015
Introduction Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015 From September 2015 the All Wales Medicines Strategy
More informationAssessing benefit/risk of medicinal products
Assessing benefit/risk of medicinal products Regulatory framework and legal implications Professor Vincenzo Salvatore Head of Legal Service London, BIICL, 29 September 2010 An agency of the European Union
More informationNon-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients
Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment
More informationGuidance for optometrist prescribers
Guidance for optometrist prescribers Contents Introduction Legislation and terminology Standards for optometrist prescribers Specialist areas of practice Section 1 - Guidance for prescribing practice P1.
More informationMELATONIN Insomnia and Sleep Disorders in Children
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which
More informationIntroduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
More informationA guide to essential gluten-free foods available from the pharmacy
A guide to essential gluten-free foods available from the pharmacy This information guide has been produced by For further information: This resource has been reviewed by the British Dietetic Association.
More informationAccess to clinical trial information and the stockpiling of Tamiflu. Department of Health
MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical
More informationGuidance for CPD Providers. Information and help for organisations providing CPD for chiropractors
Information and help for organisations providing CPD for chiropractors November 2016 What is the purpose of this guidance? The General Chiropractic Council (GCC) has a mandatory scheme of CPD for all chiropractors
More informationDRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.
Enclosure No: Agenda item No: Author: Contact: xx/xxxxx/xxxx0918 xx CEPP National Audit: Antipsychotics in Dementia All Wales Therapeutics and Toxicology Centre Tel: 02920 71 6900 awttc@wales.nhs.uk 1.0
More informationClaims about health in ads for e-cigarettes. CAP and BCAP s regulatory statement
Claims about health in ads for e-cigarettes CAP and BCAP s regulatory statement Contents 1. Executive Summary... 2 2. Policy background and the decision to consult... 4 3. Decisions... 6 4. Consequence
More informationSpanish routes for making available medicines to patients before authorisation
Spanish routes for making available medicines to patients before authorisation César Hernández García Head of Department of Medicines for Human Use Spanish Agency of Medicines and Medical Devices (AEMPS)
More informationCEPP National Audit Antipsychotics in Dementia
CEPP National Audit Antipsychotics in Dementia December 2018 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG)
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 July 2006 Doc. Ref. EMEA/186279/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON LEGAL STATUS FOR THE SUPPLY TO THE PATIENT OF CENTRALLY AUTHORISED
More informationMedicines in Scotland: What s the right treatment for me? Information for patients and the public
Medicines in Scotland: What s the right treatment for me? Information for patients and the public You can read and download this document from our website. We are happy to consider requests for other languages
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationPandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of
Pandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of one year Updated September 29 DH INFORMATION READER BOX
More informationTechnology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507
Sofosbuvir velpatasvir voxilaprevir for treating chronic hepatitis C Technology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507 NICE 2018. All rights reserved. Subject to Notice
More informationFalsified Medicines Directive (FMD) Dispensing Doctors Association Wednesday 18-Oct-17 Jerome Bertin
Falsified Medicines Directive (FMD) Dispensing Doctors Association Wednesday 18-Oct-17 Jerome Bertin Objectives What is FMD all about and when does it need to happen? Who are SecurMed and what is our role
More informationHow Might Medicinal Regulators Evolve in their Expectations for ENDS? David M Graham Chief Impact Officer - NJOY
How Might Medicinal Regulators Evolve in their Expectations for ENDS? David M Graham Chief Impact Officer - NJOY 4 Years Ago The Regulation of Nicotine-Containing Products Jeremy Mean 2015 The fact that
More informationSlow Release Opioids. Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Slow Release Opioids Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For
More information